Immunovia Publ (Sweden) Performance
| IMMNOV Stock | SEK 0.85 0.20 30.77% |
On a scale of 0 to 100, Immunovia Publ holds a performance score of 3. The company retains a Market Volatility (i.e., Beta) of 2.34, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Immunovia Publ will likely underperform. Please check Immunovia Publ's treynor ratio and the relationship between the semi variance and price action indicator , to make a quick decision on whether Immunovia Publ's current trending patterns will revert.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Immunovia publ AB are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak primary indicators, Immunovia Publ sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 468.5 M | |
| Total Cashflows From Investing Activities | -23.8 M | |
| Free Cash Flow | -176.8 M |
Immunovia |
Immunovia Publ Relative Risk vs. Return Landscape
If you would invest 86.00 in Immunovia publ AB on September 1, 2024 and sell it today you would lose (1.00) from holding Immunovia publ AB or give up 1.16% of portfolio value over 90 days. Immunovia publ AB is generating 0.4552% of daily returns and assumes 10.0786% volatility on return distribution over the 90 days horizon. Simply put, 89% of stocks are less volatile than Immunovia, and 91% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Immunovia Publ Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immunovia Publ's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Immunovia publ AB, and traders can use it to determine the average amount a Immunovia Publ's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0452
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | IMMNOV | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 10.08 actual daily | 89 89% of assets are less volatile |
Expected Return
| 0.46 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Immunovia Publ is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immunovia Publ by adding it to a well-diversified portfolio.
Immunovia Publ Fundamentals Growth
Immunovia Stock prices reflect investors' perceptions of the future prospects and financial health of Immunovia Publ, and Immunovia Publ fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immunovia Stock performance.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.26 | |||
| Operating Margin | (201.30) % | |||
| Current Valuation | 536.89 M | |||
| Shares Outstanding | 22.63 M | |||
| Price To Earning | (57.93) X | |||
| Price To Book | 2.21 X | |||
| Price To Sales | 683.47 X | |||
| Revenue | 844 K | |||
| EBITDA | (135.47 M) | |||
| Cash And Equivalents | 359.85 M | |||
| Cash Per Share | 18.42 X | |||
| Total Debt | 27.16 M | |||
| Debt To Equity | 7.80 % | |||
| Book Value Per Share | 13.09 X | |||
| Cash Flow From Operations | (152.65 M) | |||
| Earnings Per Share | (7.80) X | |||
| Total Asset | 493.81 M | |||
About Immunovia Publ Performance
By analyzing Immunovia Publ's fundamental ratios, stakeholders can gain valuable insights into Immunovia Publ's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Immunovia Publ has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Immunovia Publ has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Immunovia AB , a molecular diagnostics company, develops and commercializes diagnostic tools for cancer and autoimmune diseases in Sweden and internationally. Immunovia AB was founded in 2007 and is headquartered in Lund, Sweden. Immunovia operates under Diagnostics Research classification in Sweden and is traded on Stockholm Stock Exchange. It employs 46 people.Things to note about Immunovia publ AB performance evaluation
Checking the ongoing alerts about Immunovia Publ for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immunovia publ AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immunovia publ AB had very high historical volatility over the last 90 days | |
| Immunovia publ AB has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 844 K. Net Loss for the year was (166.63 M) with profit before overhead, payroll, taxes, and interest of 15.81 M. | |
| Immunovia publ AB has accumulated about 359.85 M in cash with (152.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 18.42, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 36.0% of the company shares are held by company insiders |
- Analyzing Immunovia Publ's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immunovia Publ's stock is overvalued or undervalued compared to its peers.
- Examining Immunovia Publ's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immunovia Publ's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immunovia Publ's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immunovia Publ's stock. These opinions can provide insight into Immunovia Publ's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Immunovia Stock analysis
When running Immunovia Publ's price analysis, check to measure Immunovia Publ's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovia Publ is operating at the current time. Most of Immunovia Publ's value examination focuses on studying past and present price action to predict the probability of Immunovia Publ's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovia Publ's price. Additionally, you may evaluate how the addition of Immunovia Publ to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Commodity Directory Find actively traded commodities issued by global exchanges |